Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Report 2025

The human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market size has grown steadily in recent years. It will grow from $1.25 billion in 2024 to $1.31 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. Growth during the historic period was driven by the increased use of companion diagnostics, greater awareness among oncologists regarding HER2 biomarkers, a stronger emphasis on personalized cancer treatments, growing interest in antibody-drug conjugates, and enhanced reimbursement policies for targeted therapies.

The human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market size is expected to see steady growth in the next few years. It will grow to $1.57 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. Growth in the forecast period is expected to result from the expanding availability of molecular diagnostic laboratories, increased awareness campaigns for gastric cancer screening, rising use of next-generation sequencing (NGS), growing demand for outpatient cancer care services, and more global regulatory approvals of HER2-targeted drugs. Key trends during this period include optimizing treatment sequencing, applying nanotechnology in drug delivery, utilizing artificial intelligence in HER2 diagnostics, enhancing antibody-dependent cellular cytotoxicity, and advancing immunotherapy combination approaches.

The increasing use of targeted cancer therapy is expected to drive growth in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market. Targeted therapy, often referred to as personalized medicine, involves treatments that block cancer growth by focusing on specific molecules involved in tumor development. This approach has gained traction due to advancements in genetic profiling, which make it possible to tailor treatments to the individual characteristics of a patient’s tumor. In the case of HER2-positive gastric cancer, targeted therapies specifically attack the HER2 protein, which is overexpressed in these tumors, helping to slow disease progression and improve patient outcomes. For example, in February 2024, the Personalized Medicine Coalition reported that the U.S. Food and Drug Administration (FDA) approved 16 new personalized medicines in 2023. These included seven cancer drugs and three others for various conditions, up from six in 2022. This trend supports the growing role of targeted therapies in cancer treatment and their contribution to the expansion of the HER2-positive gastric cancer market.

Companies in the HER2-positive gastric cancer space are also prioritizing regulatory approvals for new therapies, particularly combination treatments that integrate immunotherapy, targeted therapy, and chemotherapy. These advanced regimens aim to improve patient outcomes in first-line treatment scenarios by using immune checkpoint inhibitors to block PD-1 or PD-L1 pathways while concurrently targeting HER2 receptors and applying chemotherapeutic agents. This approach enhances anti-tumor activity and improves survival rates. In March 2025, Merck & Co., Inc., a U.S.-based biopharmaceutical company, received FDA approval for pembrolizumab (Keytruda) in combination with trastuzumab and chemotherapy. This treatment is approved for adults with HER2-positive, unresectable, or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1. Clinical results showed this combination significantly improved median progression-free survival and overall survival, with a response rate of 73% and a longer median duration of response. The approval marks a major advancement in managing advanced HER2-positive gastric cancer.

In December 2023, Pfizer Inc., a U.S.-based pharmaceutical company, acquired Seagen Inc. to enhance its portfolio of oncology therapies. This acquisition was intended to strengthen Pfizer’s capabilities in the development and delivery of targeted cancer treatments. Seagen Inc. is a U.S.-based biotechnology company known for its specialization in therapies for HER2-positive gastric cancer.

Major players in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., Bayer Aktiengesellschaft, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Genentech Inc., Ono Pharmaceutical Co Ltd., Shanghai Henlius Biotech Inc., MacroGenics Inc., Hutchison Medipharma Limited, ALX Oncology Holdings Inc., Taiho Pharmaceutical Co Ltd., Ambrx Biopharma Inc., LintonPharm Co Ltd.

North America was the largest region in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human epidermal growth factor receptor 2 (HER2)-positive gastric cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market consists of sales of trastuzumab, pertuzumab, margetuximab, and lapatinib. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market research report is one of a series of new reports that provides human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market statistics, including human epidermal growth factor receptor 2 (HER2)-positive gastric cancer industry global market size, regional shares, competitors with a human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market share, detailed human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market segments, market trends and opportunities, and any further data you may need to thrive in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer industry. This human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Human epidermal growth factor receptor 2 (HER2)-positive gastric cancer is a form of stomach or gastroesophageal junction cancer characterized by an overexpression of the HER2 protein or amplification of the HER2 gene, which drives cancer cell growth. This subtype is responsive to specific targeted therapies, leading to improved outcomes for suitable patients.

The primary treatment options for HER2-positive gastric cancer include chemotherapy, immunotherapy, radiation therapy, and targeted therapy. Chemotherapy involves the use of potent drugs that circulate through the bloodstream to kill rapidly dividing cancer cells, including those in HER2-positive gastric cancer. It is applied across different cancer stages, such as stage I through stage IV, and is utilized by various healthcare providers including ambulatory surgery centers, hospitals, specialty clinics, and others.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.